Prostate Cancer Diagnostics Market Report by Type, Test Type,End User, Country and Company Analysis 2026-2034

Global Prostate Cancer Diagnostics Market Size & Forecast 2026-2034

Global Prostate Cancer Diagnostics Market is estimated to grow at a steady rate from its current value of US$ 8.12 billion in 2025 to reach US$ 14.83 billion by 2034, with an estimated compound annual growth rate (CAGR) of 6.92% from 2026 to 2034. The increasing incidence rate of prostate cancer, combined with increased awareness of prostate cancer diagnosis, is contributing to the growth of the prostate cancer diagnostics market. Furthermore, various government programs for prostate cancer screening are also contributing to the growth of this market.

Prostate Cancer Diagnostics Market Outlooks

Prostate Cancer Diagnostics refers to the tests and procedures carried out to diagnose, monitor, and assess prostate cancer in men. These tests and procedures aim to diagnose the condition in the early stages and assess the severity and progression of the illness. They also provide the basis for the treatment process. These tests and procedures include the Prostate-Specific Antigen Test, Digital Rectal Examinations, and imaging tests such as MRI and Ultrasound. Advanced tests such as Genomic and Biomarker tests also contribute to the importance of the field.

The popularity and demand for Prostate Cancer Diagnostics have increased globally over the years due to the prevalence of Prostate Cancer in the male population. The increase in the aging population has also contributed to the growth in the field. Awareness and education on the benefits of early detection and prevention have also increased the demand for the field. Developed countries have also contributed to the growth in the field due to the well-developed healthcare infrastructure and government initiatives. Emerging economies also contribute to the growth in the field due to the development in the healthcare industry. Advanced technology in the field has also contributed to the growth in the field.

Growth Drivers of the Prostate Cancer Diagnostics Market

Rising Prevalence of Prostate Cancer and Aging Population

Worldwide, prostate cancer is the second most common cancer, closely following lung cancer. It is the fifth cause of death due to cancer, preceded by lung, liver, colorectal, and stomach cancer. An estimated 1.5 million men are diagnosed with prostate cancer every year. The incidence rate of prostate cancer varies from fewer than 3 cases per 100,000 men in Yemen and Bhutan to more than 100 cases per 100,000 men in Guadeloupe, Lithuania, Martinique, Norway, Sweden, and Barbados. One of the major factors driving the diagnostics market is the growing incidence rate of prostate cancer worldwide. Prostate cancer is one of the most common cancers found in men, especially those over the age of 50. Prostate cancer is growing due to an increase in the population over the age of 50. This is because, over time, the population is growing older, and this is causing an increase in the number of prostate cancer patients. Also, awareness campaigns are being promoted by governments as well as healthcare organizations to increase routine screenings, thereby increasing the demand for diagnostic tools. Early detection is a significant factor for survival rates and reducing healthcare costs. This increases the importance of diagnostics. This increase in patients, as well as awareness about preventive healthcare measures, is contributing greatly to the demand for prostate cancer diagnostic tools.

Advancements in Diagnostic Technologies

Technological innovation in the prostate cancer diagnostics market has led to more accurate, less invasive, and efficient detection of the condition. Conventional detection techniques such as the PSA test and biopsy are being replaced by more advanced technologies such as imaging techniques. The introduction of advanced imaging technologies such as multiparametric MRI and targeted ultrasound has improved the detection of prostate cancer. Moreover, the advent of molecular diagnostics, biomarker-based testing, and genome analysis has enabled the precise detection of the condition. The integration of artificial intelligence and machine learning technologies in imaging and detection systems has further improved the efficiency and accuracy of the detection process. The introduction of liquid biopsy has provided the opportunity for the detection of cancer in a non-invasive manner. The R&D efforts of various healthcare companies in the development of the next-generation detection technologies have created an opportunity for the growth of the technology segment in the prostate cancer diagnostics market. December 2024, The University of Texas Medical Branch Department of Pathology makes the UTMB Health System the first in Texas to integrate an artificial intelligence-based tool into the daily practice for the detection of prostate cancer. UTMB pathologists have recently begun using an Ibex-provided AI-based tool to create a digital overlay on every prostate biopsy received.

Increasing Awareness and Government Screening Initiatives

Increasing knowledge about prostate cancer and its need for early diagnosis is one factor contributing to the growth of this market. Increasing awareness among individuals, through campaigns and educational programs, about prostate cancer and its need for early diagnosis is creating a positive impact. Many countries are now adopting various programs to promote prostate cancer screening. This is highly beneficial for developed countries, as their healthcare system is well-developed. Additionally, various countries are now providing reimbursement for tests, which is helpful for individuals. The need for preventive care is also contributing to the growth of this market. As more and more individuals are becoming aware of prostate cancer, it is creating a positive impact on this market. Hence, it is estimated that more individuals are opting for early diagnosis, thereby contributing to the growth of this market. Government support for various therapies to cure prostate cancer is contributing to the growth of this market. For example, in March 2022, the FDA approved 177Lu-PSMA-617, which is a new treatment for metastatic prostate cancer. The new treatment was developed by the Society of Nuclear Medicine and Molecular Imaging. The new treatment has been proven to lower the mortality rate of patients with cancer by 38%. The new treatment was developed using PET scans to treat patients with metastatic prostate cancer who express PSMA.

Challenges of the Prostate Cancer Diagnostics Market

High Cost of Advanced Diagnostic Procedures

One of the major challenges in the prostate cancer diagnostics market is the high cost factor that is attached to the latest and most advanced diagnostic techniques. Advanced techniques like multiparametric MRI, genomic analysis, and marker-based analysis require high-end equipment and expert professionals to operate these machines. These factors contribute to the high cost factor. This is a major challenge to the prostate cancer diagnostics market, especially in low- and middle-income countries. Even in developed countries, patients might be deterred from seeking the latest and most advanced diagnostic techniques due to the high cost factor. This might have a major impact on the patient population. This is a major challenge to the prostate cancer diagnostics market. This challenge might have a major impact on the patient population.

Risk of Overdiagnosis and False Positives

Another important challenge faced in the prostate cancer diagnostics market is the possibility of over-diagnosis and false positives, mainly related to traditional screening methods. For instance, high levels of PSA are not necessarily related to cancer. There are many other benign conditions that can cause high levels of PSA, such as prostatitis or even an enlarged prostate. This may cause undue stress and may even involve unnecessary procedures such as biopsies, which can have their own risks and side effects. This has created a situation where there are questions raised by healthcare practitioners and patients regarding the accuracy of these diagnostic methods. This has therefore created a situation where there is a need for accurate diagnostic methods that can clearly distinguish between aggressive and non-aggressive cancers, thereby reducing the risks faced due to mis-diagnosis.

Benign Prostatic Hyperplasia Diagnostics Market

The market for the diagnosis of benign prostatic hyperplasia (BPH) is expanding at a moderate rate due to the increasing incidence rate of prostate enlargement among aging men. Benign prostatic hyperplasia is a non-cancerous condition in men that can have a major impact on urinary function. Therefore, it is crucial for men to seek early diagnosis of the condition. Digital rectal examination, prostate-specific antigen tests, ultrasound, urine flow tests, and others are some of the tests used for the diagnosis of the condition. In addition, the increasing awareness of men's health and the need for regular check-ups among men is also contributing to the growth of the market for the diagnosis of the condition. Furthermore, the increasing geriatric population worldwide is also contributing to the growth of the market for the diagnosis of the condition.

Small Cell Carcinoma Diagnostics Market

The small cell carcinoma diagnostics market has been gaining more and more importance due to the high malignant nature of the cancer. Small cell carcinoma, though less prevalent in the prostate area, has a high malignant rate and thus needs to be diagnosed as soon as possible. For the purpose of diagnosing the condition, imaging techniques such as CT scan, MRI, and PET scan, along with biopsy and histopathology, are being used. Additionally, the rise in the field of molecular diagnostics and the use of biomarkers to diagnose the condition more accurately have been contributing to the growth of the small cell carcinoma diagnostics market. Research and investigations in the field have also been contributing to the growth of the market. As the importance of diagnosing the condition early is being recognized, the demand for the same has been rising.

Prostate Cancer Diagnostics Preliminary Tests Market

The preliminary tests segment in the context of the diagnosis of prostate cancer has a significant impact on the early detection and evaluation of the risks associated with the condition. Blood tests involving the use of a protein called prostate-specific antigen (PSA), digital rectal exams (DRE), and imaging tests are the common preliminary tests. These tests are the most common methods used to identify possible conditions and move further in the direction of advanced tests. Awareness about the benefits associated with the early detection and diagnosis of the condition is contributing to the adoption of preliminary tests globally. Governments and healthcare organizations are encouraging the adoption of preliminary tests, especially in high-risk populations. These tests are cost-effective and easily accessible in different settings. Moreover, the accuracy associated with the tests has also improved. As the importance of preventive healthcare increases, the demand for preliminary tests in the context of the diagnosis and management of the condition also increases.

Prostate Cancer Diagnostics Hospitals Market

Hospitals are an important segment of the prostate cancer diagnostics market because they have the potential to offer integrated services for diagnosis. They have the necessary facilities, like imaging techniques, laboratory services, and qualified medical experts, which are necessary for the diagnosis of any disease. They offer a range of diagnostic techniques, from initial screening tests to highly advanced techniques like imaging and biopsies, under one umbrella. They have the facility of multi-disciplinary teams, which helps in the accurate diagnosis and treatment of any condition. They are also best for dealing with complex and high-risk conditions. This is why they are preferred by patients. Moreover, investments in the healthcare sector are on the rise, which is further enhancing the capabilities of hospitals in the diagnosis of conditions. Insurance facilities are also favorable for hospital-based diagnostic procedures. With the growing need for accurate and advanced diagnosis, hospitals are still at the forefront of the prostate cancer diagnostics market.

Prostate Cancer Diagnostics Center Market

Diagnostic centers are becoming an important segment in the prostate cancer diagnostics market because of their emphasis on providing specialized and cost-effective services. Diagnostic centers offer different types of diagnostic tests, including PSA tests, imaging tests, and biopsy tests. Diagnostic centers have fewer waiting times compared to hospitals. The demand for outpatient services is increasing in the market. Diagnostic centers offer these services, which is attracting more customers. Diagnostic centers are well-equipped with modern technologies and offer high-quality services at lower costs. Diagnostic centers are also becoming popular in the market because of the rise of diagnostic laboratories. Diagnostic centers are playing an important role in the routine screening process. They are an important part of the healthcare system. The healthcare system is shifting towards decentralization; therefore, the importance of diagnostic centers in the prostate cancer diagnostics market is likely to increase in the future.

United States Prostate Cancer Diagnostics Market

The diagnostics market for prostate cancer in the United States is well developed due to advancements in healthcare facilities and the adoption of screening programs. Awareness about the early detection of the disease and preventive healthcare is high, which encourages men, especially those aged over 50, to participate in screening programs. Moreover, the presence of key players in the diagnostics market and advancements in technology, like AI technology, support the growth of the market. Furthermore, favorable reimbursement policies provide impetus to the diagnostics market. Strong government initiatives for cancer diagnosis are present in the country. Hospitals and diagnostic centers are well equipped with advanced technologies for accurate diagnosis. The growing geriatric population and increased incidence of prostate cancer are expected to drive the diagnostics market. In March 2025, AbbVie, Inc. announced the company's early pipeline and scientific advancements in oncology research and development at the 2025 Annual Meeting of the American Association of Cancer Research (AACR). The company is presenting data on new investigational molecules ABBV-514 and ABBV-969.

United Kingdom Prostate Cancer Diagnostics Market

The United Kingdom prostate cancer diagnostics market is witnessing steady growth with the support of a strong public healthcare system and a high rate of awareness about cancer screening. The National Health Service (NHS) makes a significant contribution to the growth of the market by providing accessible and effective diagnostic services. Government initiatives and awareness campaigns also contribute to the growth of the market by promoting the early detection of the disease, especially in high-risk patients. Additionally, the adoption of advanced technologies in the field of diagnostics, such as MRI and biopsy, also boosts the growth of the market. Despite budget constraints in the public healthcare system, the government is planning to improve the efficiency and reduce the waiting time. The prevalence of the disease and the growth in the aging population also contribute to the growth of the market. Hence, the United Kingdom market will witness steady growth in the coming years. September 2024, Astellas Pharma, Inc. today presented scientific progress in advanced and hard-to-treat cancers at the 2024 congress of the European Society for Medical Oncology (ESMO). Wight abstracts across a broad range of cancer types were presented at the conference.

India Prostate Cancer Diagnostics Market

The India prostate cancer diagnostics market is growing at a rapid pace due to increased awareness of cancer and improvements in healthcare infrastructure. Awareness of prostate cancer has always been relatively low, but improvements in health education and urbanization are encouraging men to seek screening tests. Availability of diagnostics is also on the rise, especially in urban areas. This is expected to boost the India prostate cancer diagnostics market in the coming years. Although availability of diagnostics is on the rise, lack of awareness in rural areas, affordability, and availability of healthcare facilities are still issues. Availability of diagnostics in urban areas is high, so diagnostic centers in these regions are adopting high-end technology, thereby enhancing the accuracy of diagnostics. Health insurance is also on the rise, which is expected to boost the availability of diagnostics. With increased awareness and improvements in healthcare facilities, the India prostate cancer diagnostics market is expected to grow rapidly. Jan 2023: BDR Pharmaceutical, based in Mumbai, has launched the first generic Apalutamide (Apatide) for the treatment of both metastatic castration sensitive prostrate cancer as well as non-metastatic castration resistant prostrate cancer.

Saudi Arabia Prostate Cancer Diagnostics Market

The Saudi Arabia prostate cancer diagnostics market is witnessing gradual growth in the country. This growth is primarily due to the increase in health care investments and the rising health consciousness of the public about the importance of cancer diagnostics. The government of the country has been actively focusing on improving health care infrastructure in the nation. Additionally, the government has been actively involved in spreading health consciousness about the importance of health diagnostics. The use of advanced health diagnostics technologies has been witnessing gradual growth in the country. The health care infrastructure in the country has been improving gradually. The health consciousness of the public has been rising gradually. The private sector has been playing an important role in the growth of the prostate cancer diagnostics market in the country. The health care infrastructure in the country has been improving gradually. Therefore, the prostate cancer diagnostics market in the country has been witnessing gradual growth. In January 2026, ImmunityBio, Inc., which operates as a commercial-stage immunotherapy company, disclosed that the Saudi Food and Drug Authority (SFDA) has approved the commercialization of ANKTIVA(R), which is the brand name for nogapendekin alfa inbakicept in combination with Bacillus Calmette-Guerin (BCG), for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ with or

Segments

Type - Market breakup in 4 viewpoints:

1. Benign Prostatic Hyperplasia

2. Prostatic Adenocarcinoma

3. Small Cell Carcinoma

4. Others

Test Type - Market breakup in 2 viewpoints:

1. Preliminary Tests

2. Confirmatory Tests

End User - Diagnostics Market breakup in 4 viewpoints:

1. Hospitals

2. Diagnostic Centers

3. Research Institutes

4. Others

Country - Market breakup in 25 viewpoints:

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• the Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• South Africa
• Saudi Arabia
• United Arab Emirates

All the Key players have been covered from 5 Viewpoints:

• Business overview
• Key Persons
• Recent Development & Strategies
• SWOT Analysis
• Revenue Analysis

Company Analysis:

1. F. Hoffman-La Roche AG

2. Bayer AG

3. Thermo Fisher Scientific Inc.

4. Abbott Laboratories Inc.

5. Siemens Healthineers AG

6. Becton Dickinson and Company

7. Agilent Technologies Inc.

8. Hologic Inc

9. Qiagen N.V.

10. OPKO Health Inc